Bile Acid Supports Production of Blood Stem Cells
News Feb 04, 2016
Bile acids are normally found in adults, to help digest food, but in studies with pregnant mice, a research team has found large amounts of bile acids also inside the foetus.
“Foetuses produce small amounts of bile acids on their own, but here we are talking about much larger quantities. The bile acid appears to be produced by the mother and then transferred to the foetus via the placenta”, says senior author to recently released article Kenichi Miharada.
A large part of bile acid is in fact toxic for cells, but undergoes a purification process when transferred through the placenta, letting only harmless bile acid through to the foetus. It has been known that bile acid is produced in the foetal liver, but not why. Kenichi Miharada discovered that bile acid supports the production of blood stem cells in the foetal liver, and enables them to develop normally. The additional contribution from the mother is important for the foetus to develop normally.
“Our hypothesis is that the consequence of a damaged placenta, which for various reasons is unable to transfer bile acids to the foetus, can lead to leukaemia or other blood diseases later in life, and we will continue our research to see if this hypothesis holds up”, says Kenichi Miharada.
Researchers have not yet managed to get the blood-forming stem cells to produce new stem and blood cells in a laboratory. The problem with making blood stem cells proliferate outside the body is that the artificial growth gives rise to an accumulation of abnormal proteins in a part of the cell called the endoplasmic reticulum, ER. Among other things, this so-called ER stress, if the stress is severe and chronic, cause cell death.
Researcher Kenichi Miharada has previously shown that it is possible to reduce ER stress chemically by adding bile acids to the cell culture. Bile acids, which are produced naturally in the liver and stored in the gallbladder, support the protein production during the cell division process.
“Compared to other ways of trying to develop stem cells to treat blood diseases, this method is safer and quicker, because it does not involve using any artificial substances or any genetic modifications, merely a substance that already exists inside the body”, he explains.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE